ABVV

[greengiant]

Abviva, Inc. (OTC.PK: ABVV)
Abviva, Inc. was established to develop and commercialize diagnostic and therapeutic products from a novel breast cancer growth inhibitory protein. Research scientists at the prestigious University of Michigan Cancer Center discovered a secreted protein produced in normal breast epithelial cells that inhibits the growth of breast cancer.

This discovery was developed into a diagnostic blood test for breast cancer, the Mammastatin Serum Assay (MSA). The MSA will be used to screen women for early detection of breast cancer. In clinical studies Mammastatin was found to be normally present in blood serum of healthy women and absent in women with breast cancer. Abviva intends to offer the MSA to women and their doctors through its wholly owned clinical reference laboratory, Biomedical Diagnostics, LLC.

Mammastatin was also shown to be a possible treatment for breast cancer. Palliative Stage IV women with terminal breast cancer were treated with an early therapeutic preparation of Mammastatin under Compassionate Use. Most of these women presented positive responses. Over half demonstrated regression of bone metastatic tumors. Lives were extended for over two years while on the Mammastatin therapy.

Mammastatin is normally present in healthy women and therefore comes "From Life". It imparts a natural protection against breast cancer when present. When absent the risk of developing breast cancer increases. Abviva was named after this phenomenan. Abviva means "From Life".

Protecting women from breast cancer before and after diagnosis is our vision. Our mission is to innovate, develop and commercialize diagnostic and therapeutic products from Mammastatin.

Mammastatin and Breast Cancer

Mammastatin was first described as a tissue-specific growth-inhibitory protein in the journal Science by the discovering cancer research scientists at the University of Michigan Cancer Center. Mammastatin was first isolated from normal human mammary cells grown in laboratory tissue culture. The protein was identified in tissue sections within the epithelial cells lining the lumen of the mammary duct. The protein is secreted into the blood stream and can be detected by a simple blood test in human serum.  

Breast cancer cell growth is inhibited in cell culture when mammastatin is applied. This inhibition is specific to breast cancer cell lines. Most women treated under Compassionate Use with an early therapeutic preparation of Mammastatin showed improvement with their breast cancer, including reduction of bone metastases and prolonged life.

The Mammastatin Serum Assay  

The Mammastatin Serum Assay (MSA) measures a woman's risk of developing breast cancer. It is a simple blood test that detects and measures the amounts of Mammastatin in blood serum. The MSA has been studied as a means to provide early detection of women with breast cancer who have no symptoms and are undiagnosed, and to identify women who are at increased risk of developing breast cancer before cancer develops when conventional diagnostic tests are ineffective.

In clinical studies conducted on 594 women, 98% of women in the studies who had no history of breast cancer had elevated or moderate levels of mammastatin in the blood serum as measured by the Mammastatin Serum Assay. Conversely, 74% of women in the same studies who had breast cancer or who had a family history of breast cancer had no detectable levels of Mammastatin or very low levels.

A Test That Aids In Early Detection

The MSA offers a biological measure of breast cancer risk assessment so that personal and physician attention may be focused on early detection of breast cancer. When detected early women can have up to a 98% probability of surving breast cancer. The MSA is developed to help women and their physicians identify breast cancer early and and to identify women who have an elevated risk of developing breast cancer.



Diagnostic and Therapuetic Research

Mammastatin was first described in the journal Science as a tissue-specific growth-inhibitory protein that inhibited the growth of breast cancer cells. The Mammastatin Serum Assay was subsequently developed as a diagnostic test for assessing breast cancer risk and early detection. The breast cancer inhibition effects of mammastatin were confirmed during in vivo Compassionate Use studies when an early therapeutic preparation of mammastatin was administered to palliative Stage IV women with breast cancer.

Abviva's research interests are directed toward innovating and developing breast cancer diagnostic and breast cancer therapeutic products that can benefit individuals throughout the world. Abviva intends to conduct basic, translational and clinical research with biotechnology, pharmaceutical and leading university and government institutions world wide through internal and external collaborative research. We intend that research conducted on mammastatin will advance the knowledge and understanding of the biological mechanisms underlying the mammastatin phenomenon as well as advance the scientific, medical, diagnostic and therapeutic understanding of mammastatin and breast cancer.

[STOCKSEEKER]

ABVV has news out after the close yesterday. This  is one thats going to explode. The charts all show positive movement with everything heading north. This news is going to bring us some nice gains today and this week. Keep this on your radar list. Here is the latest news.

SANTA BARBARA, Calif., May 17 /PRNewswire-FirstCall/ -- Abviva, Inc. (Pink Sheets:ABVV.pk - News), a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, announced today that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company's breast cancer risk assessment test, the Mammastatin Serum Assay (MSA). The patents are the most recent of 13 international and U.S. patents to issue to the University of Michigan for breast cancer diagnostic and therapeutic uses of Mammastatin.     

"We are very pleased with this positive development," said Barrett Evans, CEO of Abviva. "Not only will these patent grants allow us to penetrate the Japanese market with proprietary technology, they further validate, along with previous patent grants covering 16 European countries, Canada, Australia, and the United States, the global patentability of the Mammastatin technology."

The MSA was initially developed at the University of Michigan Cancer Center and is licensed exclusively to Abviva by the University for scientific and commercial development as a blood test to assess women's health. In scientific correlation studies women who tested high with the MSA test showed to have lower risk of breast cancer than women who tested low. These findings align with results of the original research conducted at the University of Michigan Cancer Center that demonstrated Mammastatin was normally produced by breast epithelial cells in healthy women and was missing or reduced in transformed breast epithelial cells.

"This further solidifies the domestic and international intellectual property protection strategy we have implemented with the University of Michigan," continued Mr. Evans. "The issuance of this patent will be very important as we gain regulatory approval and market presence for the Mammastatin technology internationally. These newest patent grant notifications further expand our worldwide patent protection and marketability for MSA."